Pfizer to Close Australian Plant

Deal Watch

According to BioPharma-reporter, Pfizer will close the Australian plant at which Pfizer manufactures API for HSP-130, a biosimilar version of Amgen’s Neulasta, by 2021.  Pfizer will move production of the API to Croatia in an effort to consolidate manufacturing.  HSP130 is currently in clinical trials.
Stay tuned to the Big Molecule Watch for further developments.

Download PDF

Comments are closed.